The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Peroxisome Proliferator-Activated Receptor-γ Calls for Activation in Moderation: Lessons from Genetics and Pharmacology
Open accessAbstract
The peroxisome proliferator-activated receptor gamma (PPARgamma) is a prototypical member of the nuclear receptor superfamily and integrates the control of energy, lipid, and glucose homeostasis. PPARgamma can bind a variety of small lipophilic compounds derived from metabolism and nutrition. These ligands, in turn, determine cofactor recruitment to PPARgamma, regulating the transcription of genes in a variety of metabolic pathways. PPARgamma is the main target of the thiazolidinedione class of insulin-sensitizing drugs, which are currently a mainstay of therapy for type 2 diabetes. However, this therapy has a number of side effects. Here, we review the clinical consequences of PPARgamma polymorphisms in humans, as well as several studies in mice using general or tissue-specific knockout techniques. We also discuss the recent pharmacological literature describing a variety of new PPARgamma partial agonists and antagonists, as well as pan-PPAR agonists. The results of these studies have added to the understanding of PPARgamma function, allowing us to hypothesize a general mechanism of PPARgamma action and speculate on future trends in the use of PPARgamma as a target in the treatment of type II diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–211 of 211
Blüher, M., & Paschke, R. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-39235 · Cited by 31
Increased insulin clearance in peroxisome proliferator-activated receptor γ2 Pro12Ala
Tschritter, O., Fritsche, A., Stefan, N., Haap, M. M., Thamer, C., Bachmann, O. P., Dahl, D. B., Maerker, E., Teigeler, A., Machicao, F. E., et al. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00071-4 · Cited by 28
Genetic deficiency in Pparg does not alter development of experimental prostate cancer
Sáez, E., Olson, P., & Evans, R. M. (2003) · Nature Medicine · doi:10.1038/nm928 · Cited by 27
Dey, D., Medicherla, S., Neogi, P., Gowri, M. S., Cheng, J., Gross, C., Sharma, S., Reaven, G. M., & Nag, B. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00152-5 · Cited by 26
Arashiro, R., Katsuren, K., Fukuyama, S., & Ohta, T. (2003) · Pediatrics International · doi:10.1046/j.1442-200x.2003.01685.x · Cited by 25
O-Arylmandelic acids as highly selective human PPAR α/γ agonists
Adams, A. D., Hu, Z., Langen, D. J. V., Dadiz, A. C., Elbrecht, A., MacNaul, K. L., Berger, J. P., Zhou, G., Doebber, T. W., Meurer, R. D., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00702-9 · Cited by 24
The Pro115Gln polymorphism within the PPAR γ2 gene has no epidemiological impact on morbid obesity
Hamer, O. W., Forstner, D., Ottinger, I., Ristow, M., Bollheimer, L. C., Schölmerich, J., & Palitzsch, K. (2002) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2002-33072 · Cited by 22
Troglitazone Stimulates Pancreatic Growth in Normal Rats
Jia, D. M., & Otsuki, M. (2002) · Pancreas · doi:10.1097/00006676-200204000-00015 · Cited by 19
Doggrell, S. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.713 · Cited by 18
Pro115Gln peroxisome proliferator-activated receptor-gamma and obesity.
Shuldiner, A. R., Nguyen, W. Q., Kao, W. H. L., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.126a · Cited by 15
NISKANEN, L. K., Lindi, V., Erkkilä, A. T., Sivenius, K., Luoma, J. S., Ylä‐Herttuala, S., Laakso, M., & Uusitupa, M. I. J. (2003) · Metabolism · doi:10.1053/meta.2003.50039 · Cited by 14
Cited by
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L. C., Hauser, R., Prins, G. S., Soto, A. M., Zoeller, R. T., & Gore, A. C. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0002 · Cited by 4,585
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Self-citation
Metadata
- Authors
- Knouff, C., & Auwerx, J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-12-01
- Volume
- 25
- Issue
- 6
- Pages
- 899-918
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2058406367
- Cited by
- 256
- References
- 211
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.